December 11-13, 2024 I Geneva, Switzerland
This international event provides an advanced educational programme and showcases recent scientific developments in this promising and fast-evolving field.
From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, this event will cater to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.
About EnnoDC
EnnoDC is a clinical-stage biotech company pioneering the development of first-in-class dendritic cell-targeting IgG4 CD40 and antigen-specific immunotherapies for cancer and infectious diseases.
We have a growing pipeline of novel therapeutic antibodies, several of which are in clinical development. Target cancers include HPV16+ oropharyngeal and prostate cancer, and infectious diseases, HIV and COVID.
Our groundbreaking and versatile technology platform harnesses the power of immunotherapy and vaccines by stimulating dendritic cells (DCs) to deliver a more targeted and effective immune response compared to current treatments.
Contact
Christophe Hubert, CEO
contact@ennodc.com
